HCW Biologics signs exclusive distribution deal with Akron Biotech for HCW11-006 reagent

HCW Biologics Inc.

Exclusive worldwide distribution (ex-China) of HCW11-006 as CAR-T manufacturing reagent; 5-year term.
Advance payments: $200k at closing, $100k within 30 days of Supply Agreement, $100k on each of 1st and 2nd anniversaries.
Closing by Nov 30, 2026, subject to due diligence and product testing; Supply Agreement to be negotiated within 60 days of closing.
HCW11-006 is a multi-cytokine fusion molecule; preclinical data show CAR-Ts made with it have enhanced anti-tumor and antiviral activity.
Akron is a leading supplier of ancillary materials for cell/gene therapy; deal marks first commercialization of HCW's TRBC platform product.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.